Research programme: farnesoid X-activated receptor agonists - Chia Tai Tianqing Pharmaceutical Group

Drug Profile

Research programme: farnesoid X-activated receptor agonists - Chia Tai Tianqing Pharmaceutical Group

Alternative Names: WXS 005

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Bile acids and salts; Hepatoprotectants
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 20 Oct 2017 Preclinical trials in Non-alcoholic steatohepatitis in China (PO)
  • 20 Oct 2017 Preclinical trials in Primary biliary cirrhosis in China (PO)
  • 20 Oct 2017 Preclinical pharmacokinetics and pharmacodynamics data in Non-alcoholic steatohepatitis and Primary biliary cirrhosis presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top